To include your compound in the COVID-19 Resource Center, submit it here.

For $75M up front, Biogen will pursue Pfizer castoff for circadian rhythm in AD, PD

Biogen to evaluate Pfizer asset to normalize circadian rhythm-associated Alzheimer’s, Parkinson’s symptoms

Biogen acquired a clinical asset from Pfizer and will investigate its potential to normalize circadian rhythm to treat “sundowning” in Alzheimer’s disease and irregular sleep associated with Parkinson’s disease.

Monday’s deal is

Read the full 314 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers